CANTEX
Live / Applied — First extension granted (statement of use) (as of 17 Oct 2025)
What this means for you
Not registered yet, but its 14 Jun 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98043024
- Mark type
- Stylized text
- Filed
- 14 Jun 2023
- Published for opposition
- 04 Mar 2025
- Attorney of record
- Michael J. Belliveau
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases
- Class 044 — Medical, beauty and agricultural services: Providing medical and scientific research information about the diagnosis and treatment of diseases, namely, infectious diseases, viral diseases, and autoimmune diseases; Providing information in the fields of health, wellness, and pharmaceuticals via a website; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses
- Class 045 — Legal and security services: Licensing of pharmaceuticals and drug discovery technologies
Owner
- Cantex Pharmaceuticals, Inc., Weston, FL, US
- Cantex Pharmaceuticals, Inc., Weston, FL, US
Prosecution history
- 18 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Oct 2025 — TEAS STATEMENT OF USE RECEIVED
- 17 Oct 2025 — SOU EXTENSION 1 GRANTED
- 17 Oct 2025 — SOU EXTENSION 1 FILED
- 17 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 29 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Mar 2025 — PUBLISHED FOR OPPOSITION
- 04 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Feb 2025 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 06 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Jan 2025 — ASSIGNED TO LIE
- 17 Dec 2024 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED